Treatment advances in high-grade gliomas

被引：7

作者：

Chen, Xi ^{[1
]}

Cui, Yi ^{[2
]}

Zou, Liqun ^{[3
]}

机构：

[1] Sichuan Univ, Canc Ctr, Dept Radiotherapy, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, State Key Lab Biotherapy, Chengdu, Peoples R China

[3] Sichuan Univ, Canc Ctr, Dept Med Oncol, West China Hosp, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

high-grade gliomas; glioblastoma; cytotoxic chemotherapy; tumour treating fields; radiotherapy; targeted therapy; immunotherapy; RANDOMIZED PHASE-III; DEATH-LIGAND; LYMPHOCYTE-ACTIVATION GENE-3; NEWLY-DIAGNOSED GLIOBLASTOMA; CENTRAL-NERVOUS-SYSTEM; CAR-T-CELLS; RECURRENT GLIOBLASTOMA; IMMUNE CHECKPOINT; CANCER-IMMUNOTHERAPY; DOUBLE-BLIND;

D O I：

10.3389/fonc.2024.1287725

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-grade gliomas (HGG) pose significant challenges in modern tumour therapy due to the distinct biological properties and limitations of the blood-brain barrier. This review discusses recent advancements in HGG treatment, particularly in the context of immunotherapy and cellular therapy. Initially, treatment strategies focus on targeting tumour cells guided by the molecular characteristics of various gliomas, encompassing chemotherapy, radiotherapy and targeted therapy for enhanced precision. Additionally, technological enhancements are augmenting traditional treatment modalities. Furthermore, immunotherapy, emphasising comprehensive tumour management, has gained widespread attention. Immune checkpoint inhibitors, vaccines and CAR-T cells exhibit promising efficacy against recurrent HGG. Moreover, emerging therapies such as tumour treating fields (TTFields) offer additional treatment avenues for patients with HGG. The combination of diverse treatments holds promise for improving the prognosis of HGG, particularly in cases of recurrence.

引用

页数：19

共 207 条

[51] Recurrent glioma clinical trial, CheckMate-143: the game is not over yet [J].

Filley, Anna C. ;

Henriquez, Mario ;

Dey, Mahua .

ONCOTARGET, 2017, 8 (53) :91779-91794

[52] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].

Friedman, Henry S. ;

Prados, Michael D. ;

Wen, Patrick Y. ;

Mikkelsen, Tom ;

Schiff, David ;

Abrey, Lauren E. ;

Yung, W. K. Alfred ;

Paleologos, Nina ;

Nicholas, Martin K. ;

Jensen, Randy ;

Vredenburgh, James ;

Huang, Jane ;

Zheng, Maoxia ;

Cloughesy, Timothy .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740

[53] Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion [J].

Fritzell, Sara ;

Sanden, Emma ;

Eberstal, Sofia ;

Visse, Edward ;

Darabi, Anna ;

Siesjo, Peter .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (09) :1463-1474

[54]

Fucikova J, 2016, BLOOD, V128, P3113, DOI [10.1182/blood-2016-08-731737, 10.1182/blood-2016-08731737]

[55] Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis [J].

Fucikova, Jitka ;

Becht, Etienne ;

Iribarren, Kristina ;

Goc, Jeremy ;

Remark, Romain ;

Damotte, Diane ;

Alifano, Marco ;

Devi, Priyanka ;

Biton, Jerome ;

Germain, Claire ;

Lupo, Audrey ;

Fridman, Wolf Herve ;

Dieu-Nosjean, Marie-Caroline ;

Kroemer, Guido ;

Sautes-Fridman, Catherine ;

Cremer, Isabelle .

CANCER RESEARCH, 2016, 76 (07) :1746-1756

[56] EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma [J].

Gai, Qu-Jing ;

Fu, Zhen ;

He, Jiang ;

Mao, Min ;

Yao, Xiao-Xue ;

Qin, Yan ;

Lan, Xi ;

Zhang, Lin ;

Miao, Jing-Ya ;

Wang, Yan-Xia ;

Zhu, Jiang ;

Yang, Fei-Cheng ;

Lu, Hui-Min ;

Yan, Ze-Xuan ;

Chen, Fang-Lin ;

Shi, Yu ;

Ping, Yi-Fang ;

Cui, You-Hong ;

Zhang, Xia ;

Liu, Xindong ;

Yao, Xiao-Hong ;

Lv, Sheng-Qing ;

Bian, Xiu-Wu ;

Wang, Yan .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)

[57] The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis [J].

Ghouzlani, Amina ;

Lakhdar, Abdelhakim ;

Rafii, Soumaya ;

Karkouri, Mehdi ;

Badou, Abdallah .

SCIENTIFIC REPORTS, 2021, 11 (01)

[58] Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial [J].

Gilbert, Mark R. ;

Wang, Meihua ;

Aldape, Kenneth D. ;

Stupp, Roger ;

Hegi, Monika E. ;

Jaeckle, Kurt A. ;

Armstrong, Terri S. ;

Wefel, Jeffrey S. ;

Won, Minhee ;

Blumenthal, Deborah T. ;

Mahajan, Anita ;

Schultz, Christopher J. ;

Erridge, Sara ;

Baumert, Brigitta ;

Hopkins, Kristen I. ;

Tzuk-Shina, Tzahala ;

Brown, Paul D. ;

Chakravarti, Arnab ;

Curran, Walter J., Jr. ;

Mehta, Minesh P. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4085-+

[59] T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa [J].

Goldmann, Jana ;

Kwidzinski, Erik ;

Brandt, Christine ;

Mahlo, Jacqueline ;

Richter, Daniel ;

Bechmann, Ingo .

JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 80 (04) :797-801

[60] Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations [J].

Gong, Jun ;

Chehrazi-Raffle, Alexander ;

Reddi, Srikanth ;

Salgia, Ravi .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

← 1 2 3 4 5 6 7 8 9 10 →